- Team · Leadership & Clinical Network
Scientific Leadership Backed by a World-Class Clinical Network
ImmunoMet’s development programme is led by an experienced team and supported by specialist clinical partners, contract research organisations, and a scientific advisory board.
- Leadership
Dean Welsch, PhD — CEO & CSO
Dean Welsch is the Founder, Chief Executive Officer, and Chief Scientific Officer of ImmunoMet Therapeutics. With deep expertise in cancer metabolism and drug development, Dean leads the company’s scientific strategy, clinical programme oversight, and investor and partnership activities.
- Clinical Network
Principal Investigator — Dr. Shubham Pant
Dr. Shubham Pant serves as Principal Investigator for the Phase 1b/2a PDAC trial at MD Anderson Cancer Center, overseeing all clinical operations, enrolment, and patient care for the lixumistat programme.
Principal Investigator
MD Anderson Cancer Center · Houston, Texas
- Advisory Board
Scientific & Clinical Advisory Board
ImmunoMet is supported by a scientific and clinical advisory board providing guidance across oncology, drug development, and regulatory strategy. Full board listing to be confirmed by Dean before launch.
Advisory Board Member
MD Anderson Cancer Center · Houston, Texas
Advisory Board Member
MD Anderson Cancer Center · Houston, Texas
